|

Heart Disease Clinical Trials in Kansas

69 recruiting studies across 18 cities

All Trials in Kansas

Phase
Trial Phase Location
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3Coffeyville
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinPhase 3El Dorado
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular EventsPhase 3Hutchinson
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)Phase 3Hutchinson
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter SystemN/AKansas City
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsPhase 3Kansas City
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartPhase 3Kansas City
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart ValveN/AKansas City
Abatacept in Immune Checkpoint Inhibitor MyocarditisPhase 3Kansas City
Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPhase 3Kansas City
Assessment of CCM in HF With Higher Ejection FractionN/AKansas City
CCM OPEN HF Registry—Kansas City
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting—Kansas City
ELEVATE-HFpEF Clinical StudyN/AKansas City
Early Feasibility Study - Edwards APTURE Transcatheter Shunt SystemN/AKansas City
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACSPhase 3Kansas City
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina IIN/AKansas City
Encore PFO Closure Device - The PerFOrm TrialN/AKansas City
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry—Kansas City
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future—Kansas City
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart FailureN/AKansas City
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityPhase 3Kansas City
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and IIIN/AKansas City
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)—Kansas City
Prevail Global StudyN/AKansas City
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products—Kansas City
Product Surveillance Registry—Kansas City
Pulmonary Hypertension Biorepository and Registry—Kansas City
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE—Kansas City
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block—Kansas City
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve ReplacementN/AKansas City
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionPhase 3Kansas City
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPhase 3Kansas City
The Fourth Left Atrial Appendage Occlusion StudyN/AKansas City
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.N/AKansas City
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart FailureN/AKansas City
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFPhase 3Leavenworth
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StenosisPhase 2Overland Park
A Phase 2b Clinical Trial of YN001 in Adults With Coronary AtherosclerosisPhase 2Overland Park
Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation—Overland Park
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial FibrillationN/AOverland Park
HS Students Mandatory Universal Student Instruction in CPR Appraised Learning- Is the Mandate Working?—Overland Park
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionPhase 4Overland Park
Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry—Overland Park
Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System—Overland Park
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialPhase 3Overland Park
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387Phase 2/3Overland Park
Role of Novel ILR in the Management of PVCs—Overland Park
Tracking Results of Ablations to Combat AF Registry Generation 2—Overland Park
Use of 4D-ICE in Conjunction With TEE for Left Atrial Appendage ClosureN/AOverland Park
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II StudyN/AOverland Park
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter DefibrillatorPhase 4Shawnee Mission
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsPhase 3Topeka
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityPhase 3Wichita
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePhase 3Wichita
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic ValvesN/AWichita
AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM—Wichita
Abbott Cephea Mitral Valve Disease Registry—Wichita
Cephea Early Feasibility StudyN/AWichita
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)Phase 2/3Wichita
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart FailureN/AWichita
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRPPhase 2Wichita
EFS of the DUO System for Tricuspid RegurgitationN/AWichita
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment—Wichita
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVRN/AWichita
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery LesionsN/AWichita
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionPhase 3Wichita
SuperSaturated Oxygen Comprehensive Observational Registry—Wichita
Virtue® SAB in the Treatment of Coronary ISR TrialN/AWichita

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.